A study of Foxy-5 in patients with metastatic breast, colon or prostate cancer

Trial Profile

A study of Foxy-5 in patients with metastatic breast, colon or prostate cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2018

At a glance

  • Drugs Foxy 5 (Primary)
  • Indications Breast cancer; Colon cancer; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Feb 2018 According to a WntResearch media release,company has now decided on a revised study design, where treatment in colon cancer patients will be initiated at the time of diagnosis, before surgery has been conducted. The treatment is intended to last for a maximum of 12 weeks, or until the initiation of chemotherapy.
    • 13 Feb 2018 According to a WntResearch media release, company has revised the design of this study. The revised study design is considered to optimize the treatment effect of Foxy-5, but will delay the study initiation , the impact on the overall timeline of the study is largely offset by the fact that no dose titration of Foxy-5 will be necessary, as co-treatment with FOLFOX (a standard chemotherapy regimen) is no longer planned in the study.
    • 24 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top